admin-ajaxHarvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has hired Saverio La Francesca, MD, a veteran cardiothoracic surgeon and leading organ transplant physician, as the Company’s first Chief Medical Officer, effective April 14.

Dr. La Francesca has a unique combination of experience that features more than 25 years of academic Read more

clrxCollabRx, Inc. (CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, and Affymetrix, Inc. (AFFX), an industry leader in genomics analysis, today announced an agreement to optimize the use of CollabRx’s Genetic Variant Annotation (GVA) Service(TM) in connection with Affymetrix’ OncoScan(TM) FFPE Assay Kit and CytoScan(R) Cytogenetics Suite for analysis of gene copy number … Read more

cescaCesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today announced the restructuring of its sales, marketing and technical support organization and the appointment of Tim Lee as Director of International Sales. The restructuring is aimed at further strengthening its cord blood business and new point of care and clinical commercial programs by providing more dedicated resource leadership to each discipline.

The … Read more

admin-ajaxHarvard Apparatus Regenerative Technology, Inc.HART +5.79% , a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announces that a research team led by Paolo Macchiarini, MD, PhD at Karolinska Institutet in Sweden has successfully transplanted a regenerated esophagus into a rat using a bioreactor developed by HART. Dr. Macchiarini has previously overseen several successful regenerated trachea transplants … Read more

protea_resize_logoProtea Biosciences Group, Inc. (OTCQB:PRGB) announced today that the company’s shares of common stock have commenced trading on the OTCQB marketplace of the OTC Markets Group Inc. under the ticker symbol PRGB.

“The commencement of trading represents an important milestone for our company,” stated Steve Turner, Chief Executive Officer at Protea. “We anticipate that the initiation of trading will help us broaden our … Read more

20Intellipharmaceutics International Inc. (IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

Revenue related to the Company’s license and commercialization … Read more

nxtcpPocket Wocket
You’ve heard of the smart phone and the smart watch. Now the smart wallet is coming.

The Wocket is being touted as the next natural step in the evolution of smart devices. The NXT-ID  firm looks to introduce the smart wallet next month, calling it “a biometrically secure smart wallet with a smart card that is immediately zeroes after each transaction, making it … Read more

nxtcpA Shelton-based company plans to begin selling a tiny, pocket-sized electronic “vault” in late May. The Wocket is being promoted as “a super-smart wallet” by NXT-ID Inc.

It is essentially an e-wallet that stores credit card information, which then can be used when making transactions rather that presenting the actual credit card.

The device can be used for the various payment methods now used for … Read more

admin-ajaxStevia First Corp. (OTCQB: STVF) (“Stevia First” or the “Company”), an early-stage agribusiness based in California’s Central Valley growing region and focused on the commercial scale production of stevia, the all-natural zero-calorie sweetener that is rapidly transforming the food and beverage industry, is pleased to announce that Doug Grubb, Ph.D. has accepted a position on the Company’s Scientific Advisory Board and that Brandon … Read more

mesologoMesoblast recently completed enrollment for its double-blind, placebo-controlled Phase 2 clinical trial at multiple sites across the United States and Australia to randomize 100 patients with intervertebral disc disease to receive either high doses of the company’s allogeneic MPCs with hyaluronic acid carrier, hyaluronic acid carrier alone or saline solution.

“A theoretical advantage of this treatment is that if we are able to help a … Read more